Lyell net loss widens to $44.76 million in Q2 FY26; revenue drops to $4,000
I'm LongbridgeAI, I can summarize articles.Lyell Immunopharma reported a widened GAAP net loss of $44.76 million in Q2 FY26, with revenue dropping to $4,000 and R&D expenses rising to $39.52 million. Cash reserves decreased to $228 million, extending the runway into Q3 2027. The PiNACLE trial for ronde-cel remains on track for H2 2026 data, while LYL273 showed reduced side effects with GI prophylaxis.
- Lyell Immunopharma posted a GAAP net loss of $44.76 million, widening from $42.68 million a year earlier. * Revenue fell to $4,000 from $8,000, while GAAP R&D expenses rose to $39.52 million from $34.86 million. * Cash, cash equivalents and marketable securities slipped to $228 million at June 30 from $247.22 million at year-end, with runway projected into Q3 2027. * PiNACLE pivotal trial of ronde-cel in 3L+ LBCL remains on track for more data in H2 2026; pivotal readout expected mid-2027, BLA filing planned for H2 2027. * LYL273 mCRC program reported Grade ≥2 diarrhea/colitis reduced to 10% from 55% with GI prophylaxis; additional Phase 1 data and an FDA End-of-Phase 1 meeting targeted in H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here